Dyadic to Present at 2022 Jefferies Healthcare Conference
June 02, 2022 09:27 ET
|
Dyadic International, Inc.
JUPITER, Fla., June 02, 2022 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on further improving, applying and...
Blue Water Vaccines Announces Sponsored Research Agreement Amendment to Continue Funding Universal Influenza Vaccine Development at The University of Oxford
May 31, 2022 08:30 ET
|
Blue Water Vaccines Inc.
CINCINNATI, May 31, 2022 (GLOBE NEWSWIRE) -- Blue Water Vaccines Inc. (“BWV” or “Blue Water Vaccines” or “the Company”) a biopharmaceutical company developing transformational vaccines to address...
Blue Water Vaccines Announces Collaboration with Instituto Butantan for the Development of BWV-101, a Universal Influenza Vaccine Candidate
May 19, 2022 14:00 ET
|
Blue Water Vaccines Inc.
CINCINNATI, May 19, 2022 (GLOBE NEWSWIRE) -- Blue Water Vaccines, Inc. (“BWV” or “Blue Water Vaccines” or “the Company”) a biopharmaceutical company developing vaccines, announces a collaboration...
Blue Water Vaccines Reports First Quarter 2022 Financial Results and Recent Business Developments
May 13, 2022 17:01 ET
|
Blue Water Vaccines Inc.
Closed initial public offering of 2,222,222 shares of common stock at a public offering price of $9.00 per share, with aggregate gross proceeds of approximately $20 millionMultiple vaccine candidate...
Blue Water Vaccines Inc. to Present at H.C. Wainwright Global Investment Conference
May 12, 2022 08:30 ET
|
Blue Water Vaccines Inc.
CINCINNATI, May 12, 2022 (GLOBE NEWSWIRE) -- Blue Water Vaccines Inc. (“BWV” or “Blue Water Vaccines” or “the Company”) a biopharmaceutical company developing transformational vaccines to address...
Dyadic Announces Successful Toxicology Data Published in “Toxicologic Pathology”
May 09, 2022 08:30 ET
|
Dyadic International, Inc.
Toxicology data published in the international peer-reviewed scientific journal “Toxicologic Pathology” demonstrates excellent safety profile and lasting immunogenic response from Dyadic’s DYAI-100,...
Vir Biotechnology to Provide Corporate Update and Report First Quarter 2022 Financial Results on May 5, 2022
April 21, 2022 16:05 ET
|
Vir Biotechnology, Inc.
SAN FRANCISCO, April 21, 2022 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the Company will provide a corporate update and report financial results for the first quarter...
Blue Water Vaccines Presents New Data Supporting Universal Influenza Vaccine Candidate at the World Vaccine Congress 2022 in Washington, DC
April 21, 2022 08:45 ET
|
Blue Water Vaccines Inc.
CINCINNATI, April 21, 2022 (GLOBE NEWSWIRE) -- Blue Water Vaccines Inc. (“BWV” or “Blue Water Vaccines” or “the Company”), a biopharmaceutical company developing transformational vaccines, today...
Isothermal Nucleic Acid Amplification Technology Market to cross USD 2.8 Billion by 2028: Global Market Insights Inc.
April 20, 2022 06:30 ET
|
Global Market Insights Inc.
Selbyville, Delaware , April 20, 2022 (GLOBE NEWSWIRE) -- The isothermal nucleic acid amplification technology (INAAT) market value is projected to reach USD 2.8 billion by 2028, according to a...
Blue Water Vaccines Announces $8 Million Private Placement Priced At-the-Market Under Nasdaq Rules
April 13, 2022 09:30 ET
|
Blue Water Vaccines Inc.
CINCINNATI, April 13, 2022 (GLOBE NEWSWIRE) -- Blue Water Vaccines Inc. (“BWV” or “Blue Water Vaccines” or “the Company”), a biopharmaceutical company developing transformational vaccines to address...